The USAID/TSP HIV Child and Adolescent ARV Procurement Forecasting Tool is intended to assist program managers, clinicians and support staff in quantifying and budgeting for a program’s child and adolescent ARV needs. The tool: i) allows the user to insert the number of children and adolescents needing ARVs; and ii) provides an output describing how the children and adolescents are expected to transition into different weight bands over time.
The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. CROI 2019 will be held from March 4 to March 7, 2019, at the Washington State Convention Center in Seattle, Washington.
The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics, from new antiretroviral drugs, AIDS-related complications, and opportunistic infections, to promoting adherence and ethical issues.
The HIV New Product Introduction Toolkit provides Ministries of Health (MoHs) and implementing partners with the tools necessary to evaluate the adoption and introduction of new products in their local context. The toolkit includes a wide-range of information, tools, and resources spanning the entire chain of product introduction including product adoption, forecasting, procurement, facility phase-in, and supply planning and monitoring, ensuring that products reach those in need of them.
HIV New Product Introduction Guide: A framework for supporting new product introduction in national health systems
Over the past two decades, the landscape of medications used to treat HIV has evolved rapidly. Treatment options have improved dramatically with the development and availability of more efficacious, safer, and more tolerable antiretrovirals (ARVs). These options allow national treatment programs to better serve the needs of their patients, support significant treatment scale-up, reduce costs, and achieve public health goals. Use of the most optimal regimens and products offers many benefits to national HIV programs and people living with HIV (PLHIV).
The Southern African HIV Clinicians Society’s biannual conference focuses on clinical content for HIV and TB health care workers. The 2018 conference programme has been carefully designed to benefit all health care practitioners, with topics ranging from new antiretroviral drugs, AIDS-related complications, opportunistic infections, promoting adherence and ethical issues.
HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study
HIV drug resistance (HIVDR) poses a threat to future antiretroviral therapy success. Monitoring HIVDR patterns is of particular importance in populations such as sex workers (SWs), where documented HIV prevalence is between 34-89%, and in countries with limited therapeutic options. Currently in South Africa, there is a dearth in evidence and no ongoing surveillance of HIVDR amongst sex work populations. This study aims to describe the prevalence of HIVDR amongst a sample of female sex workers (FSWs) from Soweto, South Africa.
Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS. Systemic infections are mainly with Pneumocystis jirovecii (pneumocystosis), Cryptococcus neoformans (cryptococcosis), Histoplasma capsulatum (histoplasmosis), and Talaromyces (Penicillium) marneffei (talaromycosis). The incidence of systemic fungal infections has decreased in people with HIV in high-income countries because of the widespread availability of antiretroviral drugs and early testing for HIV.
Approximately 1.4 million women living with HIV become pregnant every year. Most women use antiretroviral therapy, to reduce the risk of vertical transmission or for personal health reasons. Using the GRADE framework according to the BMJ Rapid Recommendation process, we make recommendations for optimal choice of combination antiretroviral regimen considering patient values and preferences, the balance of desirable and undesirable outcomes, their uncertainty, and practical issues.